Kiromic BioPharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Kiromic BioPharma generated cash of -$21,225,300, which is more than the previous year. Cash used in financing activities reached the amount of $23,990,700 last year. Net change in cash is therefore $2,558,800.
Cash Flow
| 2018 | -2.15M | -137.3K | 1.62M |
|---|---|---|---|
| 2019 | -2.91M | -302.7K | 4.76M |
| 2020 | -6.12M | -1.45M | 15.80M |
| 2021 | -20.32M | -1.81M | 37.33M |
| 2022 | -23.74M | -4.86M | 3.90M |
| 2023 | -21.22M | -206.6K | 23.99M |
KRBP Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 645.2K | 25.35M | 10.15M | 1.92M | 384.3K | 1.04M |
Operating activities | ||||||
Net income | -20.94M | -34.73M | -25.58M | -19.20M | -3.72M | -3.81M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 2.22M | 1.67M | 469.8K | 200K | 87.5K | 80.9K |
Stock-based compensation expense | 141.3K | 1.23M | 3.76M | 13.24M | 522.9K | 0 |
| Deferred income tax benefit | 141.3K | 1.23M | 3.76M | 13.24M | 522.9K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 16.2K | 9.8K | 0 | -78.8K | 0 |
Inventories | 0 | 0 | 0 | 0 | -5.9K | 0 |
Accounts payable | -5.03M | 3.79M | 1.41M | -7.7K | 293.4K | -4.4K |
Cash generated by operating activities | -21.22M | -23.74M | -20.32M | -6.12M | -2.91M | -2.15M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -206.6K | -4.88M | -1.89M | -1.45M | -302.7K | -137.3K |
Acquisitions Net | 0 | 15K | 84K | 0 | 0 | 0 |
Cash generated by investing activities | -206.6K | -4.86M | -1.81M | -1.45M | -302.7K | -137.3K |
Financing activities | ||||||
Common Stock Issued | 659.1K | 0 | 40M | 15M | 4.51M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 23.44M | 4.10M | -573.7K | -188.1K | 250K | 0 |
Cash used in financing activities | 23.99M | 3.90M | 37.33M | 15.80M | 4.76M | 1.62M |
Net Change In Cash | 2.55M | -24.70M | 15.20M | 8.22M | 1.54M | -665.2K |
Cash at end of period | 3.20M | 645.2K | 25.35M | 10.15M | 1.92M | 384.3K |
| Data source | Data source | Data source | Data source |